Musk's X down for tens of thousands of US users, Downdetector shows-March 2024-www.financetom.com

Musk's X down for tens of thousands of US users, Downdetector shows

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Musk's X down for tens of thousands of US users, Downdetector shows

Mar 28, 2025 12:30 PM

(Reuters) - Elon Musk's X was down for tens of thousands of users in the U.S. on Friday, according to outage tracking website Downdetector.com.

There were more than 53,000 incidents of people reporting issues with the social media platform as of 2:48 p.m. ET, Downdetector showed, which tracks outages by collating status reports from a number of sources.

X did not immediately respond to Reuters' request for comment.

Previous page： --Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024 Next page： FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Street Color: L3Harris Technologies to Reportedly Eliminate 5% of Workforce in 2024

Apr 23, 2024

03:10 PM EDT, 04/23/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 208.32, Change: +0.18, Percent...

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

Apr 23, 2024

Tuesday, Novartis AG ( NVS ) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugmaker’s Q1 Earnings...

Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says

Apr 23, 2024

03:08 PM EDT, 04/23/2024 (MT Newswires) -- Starbucks' ( SBUX ) 2024 outlook will likely be affected by near-term pressures, but it remains well-positioned in the long term due to strong customer brand affinity and an attractive growth profile, UBS said in a note emailed Tuesday. Challenges in the US stem from protests related to Middle East conflict and pressure...

Foreigners add net $32.7 bln to EM portfolios in March -IIF

Apr 23, 2024

NEW YORK, April 23 (Reuters) - Foreigners added about $32.7 billion to their emerging market portfolios in March, a fifth consecutive month of overall foreign net flows to EMs, the Institute of International Finance said on Tuesday. The IIF banking trade group said flows were positive for both bonds and equities last month, with equities absorbing $10.2 billion and debt...